BRIEF published on 07/01/2025 at 08:59, 8 months 15 days ago GenSight Biologics raises nearly €4 million in private placement Private Placement Investment GenSight Biologics Euronext Shares LUMEVOQ ®
PRESS RELEASE published on 07/01/2025 at 08:54, 8 months 15 days ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics successfully completes private placement of nearly EUR 4 million, attracting new international investors. Funds to advance gene therapies for retinal diseases and CNS disorders Private Placement GenSight Biologics Gene Therapies Retinal Diseases CNS Disorders
BRIEF published on 06/26/2025 at 07:35, 8 months 20 days ago GenSight Biologics: Advances in Manufacturing Partnership with Catalent Gene Therapy GenSight Biologics LUMEVOQ® NOHL Catalent
PRESS RELEASE published on 06/26/2025 at 07:30, 8 months 20 days ago Inside Information / Other news releases GenSight Biologics achieves significant milestone with new manufacturing partnership with Catalent, successfully transferring upstream phase of LUMEVOQ® manufacturing process Gene Therapy GenSight Biologics LUMEVOQ Catalent Manufacturing Partnership
BRIEF published on 05/13/2025 at 22:05, 10 months 2 days ago GenSight Biologics Shareholders Approve Majority of Board's Resolutions Shareholder Meeting Board Resolutions GenSight Biologics LUMEVOQ® Phase III RECOVER
PRESS RELEASE published on 05/13/2025 at 22:00, 10 months 2 days ago Inside Information / Other news releases GenSight Biologics announces approval of all resolutions at Combined General Meeting on May 13, 2025. Company highlights achievements of 2024 and strategic priorities for 2025 Strategic Priorities Approval Combined General Meeting GenSight Biologics Achievements
BRIEF published on 04/23/2025 at 20:35, 10 months 22 days ago GenSight Biologics Announces Annual General Meeting Details Annual General Meeting Shareholders Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 04/23/2025 at 20:30, 10 months 22 days ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 13, 2025 at 2:00 pm CEST in Paris, France. Procedures for obtaining preparatory documents outlined Annual General Meeting Preparatory Documents GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 04/08/2025 at 07:51, 11 months 8 days ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
BRIEF published on 04/08/2025 at 07:48, 11 months 8 days ago GenSight Biologics Files 2024 Universal Registration Document Universal Registration Document GenSight Biologics Gene Therapies Retinal Diseases Financial Report 2024
Published on 03/16/2026 at 13:00, 23 minutes ago Aeonian Commences Inaugural Drill Program at the Jake Zone, Koocanusa Copper-Silver Project, Southeastern British Columbia
Published on 03/16/2026 at 12:30, 53 minutes ago Sterling Metals Intersects 235.5m at 0.42% Cu and 0.042 g/t Au including 32.75m at 1.31% Cu and 0.11 g/t Au and Discovers New Bornite-Covellite Zone
Published on 03/16/2026 at 12:30, 53 minutes ago Electric Metals (USA) Limited Announces Agreement to Sell Non-Core Nevada Silver Assets
Published on 03/16/2026 at 12:30, 53 minutes ago Eskay Continues to Build its EXPLORATION TEAM for the 2026 Season
Published on 03/16/2026 at 12:30, 53 minutes ago Digi Power X Provides Clarification on US Data Centers Transaction
Published on 03/16/2026 at 12:21, 1 hour 1 minute ago North Peak Announces Initial $4.38 Million Closing for Previously Announced Non-Brokered Private Placement
Published on 03/16/2026 at 12:18, 1 hour 4 minutes ago Commerzbank takes note of UniCredit’s unsolicited takeover attempt
Published on 03/16/2026 at 12:15, 1 hour 7 minutes ago Commerzbank takes note of UniCredit’s unsolicited takeover attempt
Published on 03/16/2026 at 12:12, 1 hour 10 minutes ago Aroundtown SA: Release of a capital market information
Published on 03/16/2026 at 08:30, 4 hours 53 minutes ago CDA - Update on CDA' parks solarization program
Published on 03/13/2026 at 19:50, 2 days 17 hours ago Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 19 hours ago Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 5 hours ago BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 19 hours ago NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS
